Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 13INDUSTRY 4NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 132Lymphoid 82Other hematologic neoplasm 23Myeloid 5Genitourinary 4Dermatologic 3Tumor-Agnostic 2Thoracic 2Gynecologic 2Gastrointestinal 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Classical hematology 1

Conditions

Prostatic Neoplasms 2Wilms Tumor 1Multiple Myeloma 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 164Prednisone 129enzalutamide 125Docetaxel 122Abiraterone Acetate 94Nivolumab 92Gemcitabine 71Sunitinib 67atezolizumab 49Leuprolide 49acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 48abiraterone 48Cisplatin 48Sorafenib 39radium Ra 223 dichloride 38Ipilimumab 38darolutamide 37apalutamide 37Carboplatin 37Prednisolone 33Everolimus 33Axitinib 32avelumab 31pazopanib 30cabozantinib 30Bevacizumab 30Paclitaxel 29enfortumab vedotin 28bicalutamide 28Cyclophosphamide 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Lenalidomide × Genitourinary × Clear all
NCT01827137 2024-09-19

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Sellas Life Sciences Group

Phase 1/2 Completed
20 enrolled 9 charts
GenitourinaryPlasma cell

Multiple Myeloma, Wilms Tumor

NCT00975806 2019-11-25

Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma

Celgene

Phase 1/2 Terminated
16 enrolled 13 charts
Genitourinary

Carcinoma, Renal Cell

NCT00988208 2018-04-04

Mainsail

Celgene

Phase 3 Completed
1,059 enrolled 27 charts
Genitourinary

Prostatic Neoplasms

NCT00179738 2005-11-23

A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.

Celgene

Phase 2 Terminated
40 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡